<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="356">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156515</url>
  </required_header>
  <id_info>
    <org_study_id>2021KT111</org_study_id>
    <nct_id>NCT05156515</nct_id>
  </id_info>
  <brief_title>PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor</brief_title>
  <official_title>PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to construct a noninvasive approach using 68Ga-THP-APN09&#xD;
      PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma&#xD;
      and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MPR</measure>
    <time_frame>After 2-4 cycles of immunotherapy (each cycle is 28 days)</time_frame>
    <description>In the surgical pathology after neo-adjuvant immunotherapy, the proportion of active tumors was less than 10%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Melanoma</condition>
  <condition>PD-L1</condition>
  <condition>PET/CT</condition>
  <arm_group>
    <arm_group_label>Imaging cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-THP-APN09 PET/CT scans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-THP-APN09</intervention_name>
    <description>APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.</description>
    <arm_group_label>Imaging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75, male and female, with ECOG score of 0 or 1;&#xD;
&#xD;
          2. Subjects with head and neck tumors, lung cancer, esophageal cancer, breast cancer,&#xD;
             ovarian cancer, cholangiocarcinoma, colorectal cancer, gastric cancer, pancreatic&#xD;
             cancer, melanoma, bone or soft tissue sarcoma, solid tumors or suspected tumor&#xD;
             subjects who intend to undergo pathological tissue biopsy or receive tumor surgical&#xD;
             treatment in the near future (within 2 months);&#xD;
&#xD;
          3. The expected survival was more than 26 weeks;&#xD;
&#xD;
          4. Blood routine test, liver and kidney function meet the following standards: blood&#xD;
             routine: WBC &gt;= 4.0 x 10^9/L or neutrophil &gt;= 1.5 x 10^9/:, PLT &gt;= 100 x 10^9 / L, Hb&#xD;
             &gt;= 90g / L; Pt or APTT &lt;= 1.5 upper limit of normal value; liver and kidney function:&#xD;
             total bilirubin &lt;= 1.5 x ULT (upper limit of normal value), ALT / AST &lt;= 2.5 upper&#xD;
             limit of normal value or &lt;= 5 x ULT (subject with liver metastasis), ALP &lt;= 2.5 upper&#xD;
             limit of normal value (if bone metastasis or liver metastasis exists, ALP &lt;= 4.5 upper&#xD;
             limit of normal value); BUN &lt;= 1.5 x ULT, SCR &lt;= 1.5 x ULT;&#xD;
&#xD;
          5. According to RECIST1.1, there was at least one measurable target lesion;&#xD;
&#xD;
          6. Women must take effective contraceptive measures during the study period and within 6&#xD;
             months after the end of the study; men should agree to use contraceptive measures&#xD;
             during the study period and within 6 months after the end of the study period;&#xD;
&#xD;
          7. Understand and sign informed consent voluntarily with good compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The function of liver and kidney was seriously abnormal;&#xD;
&#xD;
          2. Preparation for pregnant, pregnant and lactating women;&#xD;
&#xD;
          3. Inability to lie flat for half an hour;&#xD;
&#xD;
          4. Suffering from claustrophobia or other mental disorders; 5) Other researchers&#xD;
             considered it unsuitable to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Zhu</last_name>
    <phone>010-88196495</phone>
    <email>zhuhuabch@pku.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Zhu</last_name>
      <phone>010-88196495</phone>
      <email>zhuhuabch@pku.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

